Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients
Abstract
Standard-of-care first-line therapy for patients with newly diagnosed glioblastoma (ndGBM) is maximal safe surgical resection, then concurrent radiotherapy and temozolomide, followed by maintenance temozolomide. IGV-001, the first product of the Goldspire™ platform, is a first-in-class autologous immunotherapeutic product that combines personalized whole tumor–derived cells with an antisense oligonucleotide (IMV-001) in implantable biodiffusion chambers, with the intent to induce a tumor-specific immune response in patients with ndGBM. Here, we describe the design and rationale of a randomized, double-blind, phase IIb trial evaluating IGV-001 compared with placebo, both followed by standard-of-care treatment in patients with ndGBM. The primary end point is progression-free survival, and key secondary end points include overall survival and safety.
Plain language summary – IGV-001 in newly diagnosed glioblastoma
Glioblastoma (GBM) is a fast-growing brain tumor that happens in about half of all gliomas. Surgery is the first treatment for patients with newly diagnosed GBM, followed by the usual radiation and chemotherapy pills named temozolomide. Temozolomide pills are then given as a long-term treatment. The outcome for the patient with newly diagnosed GBM remains poor. IGV-001 is specially made for each patient. The tumor cells are removed during surgery and mixed in the laboratory with a small DNA, IMV-001. This mix is the IGV-001 therapy that is designed to give antitumor immunity against GBM. IGV-001 is put into small biodiffusion chambers that are irradiated to stop the growth of any tumor cells in the chambers. In the phase IIb study, patients with newly diagnosed GBM are chosen and assigned to either the IGV-001 or the placebo group. A placebo does not contain any active ingredients. The small biodiffusion chambers containing either IGV-001 or placebo are surgically placed into the belly for 48 to 52 h and then removed. Patients then receive the usual radiation and chemotherapy treatment. Patients must be adults aged between 18 and 70 years. Patients also should be able to care for themselves overall, but may be unable to work or have lower ability to function. Patients with tumors on both sides of the brain are not eligible. The main point of this study is to see if IGV-001 helps patients live longer without making the illness worse compared with placebo.
Clinical Trial Registration:NCT04485949 (ClinicalTrials.gov)
Graphical abstract
Tweetable abstract
IGV-001, an autologous cell biologic-device product, is being tested versus placebo, each followed by standard of care, in a randomized phase IIb trial in newly diagnosed glioblastoma. IGV-001, designed to induce antitumor immunity, is delivered via implantable biodiffusion chambers.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. The epidemiology of glioma in adults: a “state of the science” review. Neuro. Oncol. 16(7), 896–913 (2014).
- 2. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol. Biomarkers Prev. 23(10), 1985–1996 (2014).
- 3. ; for the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987–996 (2005). •• Provides the treatment guidelines for the treatment of patients with glioblastoma.
- 4. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis. Int. J. Radiat. Oncol. Biol. Phys. 91(1), 109–115 (2015).
- 5. Delaying standard combined chemoradiotherapy after surgical resection does not impact survival in newly diagnosed glioblastoma patients. Radiother. Oncol. 118(1), 9–15 (2016).
- 6. Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database. J. Clin. Oncol. 27(5), 733–739 (2009).
- 7. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N. Engl. J. Med. 376(11), 1027–1037 (2017).
- 8. Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database. Neuro. Oncol. 20(7), 966–974 (2018).
- 9. Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro. Oncol. 19(8), 1119–1126 (2017).
- 10. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Neurology 88(15), 1422–1430 (2017).
- 11. . Molecular biomarkers in glioblastoma: a systematic review and meta-analysis. Int. J. Mol. Sci. 23(16), 8835 (2022).
- 12. MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: a pooled analysis of four clinical trials. Clin. Cancer Res. 25(6), 1809–1816 (2019).
- 13. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997–1003 (2005).
- 14. IGF-IR: a new prognostic biomarker for human glioblastoma. Br. J. Cancer 113(5), 729–737 (2015).
- 15. . Role of insulin-like growth factor 1 receptor signalling in cancer. Br. J. Cancer 92(12), 2097–2101 (2005).
- 16. . Evidence for the possible biological significance of the igf-1 gene alternative splicing in prostate cancer. Front. Endocrinol. (Lausanne) 4, 31 (2013).
- 17. . Clinical studies in humans targeting the various components of the IGF system show lack of efficacy in the treatment of cancer. Mutat. Res. Rev. Mutat. Res. 772, 105–122 (2017).
- 18. State of the art and future perspectives for the use of insulin-like growth factor receptor 1 (IGF-1R) targeted treatment strategies in solid tumors. Discov. Med. 11(57), 144–153 (2011).
- 19. . Effect of the insulin-like growth factor I receptor on ionizing radiation-induced cell death in mouse embryo fibroblasts. Exp. Cell Res. 235(1), 287–294 (1997).
- 20. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 57(15), 3079–3083 (1997).
- 21. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res. 58(15), 3353–3361 (1998).
- 22. . Challenges and opportunities for immunotherapeutic intervention against myeloid immunosuppression in glioblastoma. J. Clin. Med. 11(4), 1069 (2022).
- 23. . The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur. J. Cancer 43(13), 1895–1904 (2007).
- 24. . The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 13(1), 16–24 (2008).
- 25. . Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol. Cancer Ther. 6(1), 1–12 (2007).
- 26. Phase Ib clinical trial of IGV-001 for patients with newly diagnosed glioblastoma. Clin. Cancer Res. 27(7), 1912–1922 (2021). •• Describes the results of the initial single-center phase Ia pilot study (NCT01550523), evaluating safety and feasibility of IGV-001 in patients with malignant astrocytoma. The findings show that IGV-001 is well tolerated, progression-free survival compares favorably with standard of care, and evidence suggests an immune-mediated mechanism.
- 27. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J. Clin. Oncol. 19(8), 2189–2200 (2001). •• Describes the results of another single-center phase Ib study (NCT02507583), evaluating safety and preliminary clinical activity of IGV-001 in patients with newly diagnosed glioblastoma. The findings show that treatment with IGV-001 induces apoptosis and a host response in vivo without unusual side effects. Subsequent transient and sustained radiographic and clinical improvements warrant further clinical investigations.
- 28. . Potential role of CSF cytokine profiles in discriminating infectious from non-infectious CNS disorders. PLoS One 13(10), e0205501 (2018).
- 29. Glioblastoma exosomes and IGF-1R/AS-ODN are immunogenic stimuli in a translational research immunotherapy paradigm. Cancer Immunol. Immunother. 64(3), 299–309 (2015).
- 30. Enhancement of glioma-specific immunity in mice by “NOBEL”, an insulin-like growth factor 1 receptor antisense oligodeoxynucleotide. Cancer Immunol. Immunother. 64(4), 447–457 (2015).
- 31. Personalized immunotherapeutic platform with evidence of clinical activity in glioblastoma protects mice against ovarian liver and bladder cancer tumor challenges. J. Immunother. Cancer 10(Suppl. 2), A1113 (Abstract 1398) (2022). • This preclinical study shows that the durable antitumor activity of IGV-001 in multiple cancers (ovarian, liver and bladder) is associated with a systemic immunologic response resulting in generation of T helper 1 antitumor cytotoxic T cells.
- 32. Personalized immunotherapeutic platform with evidence of clinical activity in glioblastoma (IGV-001) protects mice against other lethal solid tumor challenges. Cancer Res. 82(Suppl. 12), Abstract 626 (2022).
- 33. . Autologous tumor cell immunotherapeutic platform, with evidence of clinical activity in glioblastoma, induces in vitro immune responses in both glioblastoma and endometrial cancer. Presented at: CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON). New York, NY, USA (2022). • This preclinical study shows that IGV-001 induces in vitro immune responses in glioblastoma cancer cells, including dendritic cell maturation, CD4+ and CD8+ T cell activation, and increases in central effector memory T cells.
- 34. Autologous glioblastoma tumor cells and an antisense oligonucleotide against insulin-like growth factor type 1 receptor protect against tumor challenge and generate T cell anti-tumor responses. J. Immunother. Cancer 9(Suppl. 2), A231 (Abstract 218) (2021). • This preclinical study shows that IGV-001 generates strong antitumor responses in a glioblastoma mouse model, by stimulating the immune system and suppressing tumor growth.
- 35. A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma. J. Immunother. Cancer 11(8), e006880 (2023). • This preclinical study demonstrates that IGV-001 elicits immunogenic cellular stress, culminating with bona fide immunogenic cell death and the activation of therapeutically relevant, T helper 1–polarized immune responses against glioblastoma.
- 36. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370(8), 709–722 (2014).
- 37. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370(8), 699–708 (2014).
- 38. ; on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, the National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10(5), 459–466 (2009).
- 39. . Response assessment in neuro-oncology clinical trials. J. Clin. Oncol. 35(21), 2439–2449 (2017).
- 40. . Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 57(1), 289–300 (1995).
